Skip to main content
Biomark Diagnostics Inc. logo

Biomark Diagnostics Inc. — Investor Relations & Filings

Ticker · BUX ISIN · CA09073K1084 LEI · 529900UHZ378KKXOLY69 CSE Professional, scientific and technical activities
Filings indexed 398 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country CA Canada
Listing CSE BUX

About Biomark Diagnostics Inc.

https://www.biomarkdiagnostics.com/

Biomark Diagnostics Inc. is an oncology-focused company developing advanced liquid biopsy diagnostic technologies for the early detection, monitoring, and screening of cancer. The core technology platform utilizes metabolomics, the study of biomarkers and metabolites, integrated with Artificial Intelligence and Machine Learning algorithms. This approach aims to provide rapid, accurate results for hard-to-detect cancers, thereby improving patient outcomes. The company's pipeline includes the Liquid Biopsy SSAT1 Assay and a Metabolic Panel.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 25% confidence The document is a corporate press release announcing BioMark Diagnostics’ selection to present at a research forum and describing its technology and forward-looking statements. It is not an earnings release, financial report, board change, capital update, or any of the specific filings listed. It is a general corporate announcement without regulatory filing specifics, so it falls into the fallback category Regulatory Filings (RNS).
2026-04-14 English
News release - English.pdf
Regulatory Filings Classification · 20% confidence The document is a press release announcing that BioMark Diagnostics will present its liquid biopsy platform at a research forum. It does not contain financial results (ER/IR/10-K/IR), capital/financing details (CAP), changes in management (MANG), voting or AGM materials (AGM-R/DVA), dividends (DIV), M&A (TAR), share transactions (DIRS/POS/SHA), ESG metrics (SR), or other specific report types. It also is not an investor presentation deck (IP) but rather a general corporate news release. It does not correspond to any dedicated category, so it falls under the fallback “Regulatory Filings” category (RNS).
2026-04-14 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2026-03-02 English
Interim financial statements/report – English.pdf
Regulatory Filings
2026-03-02 English
News release - English.pdf
Regulatory Filings
2026-01-15 English
News release - English.pdf
Regulatory Filings
2025-12-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.